AP756A - Dipeptide compounds which are growth hormone secretagoques. - Google Patents

Dipeptide compounds which are growth hormone secretagoques. Download PDF

Info

Publication number
AP756A
AP756A APAP/P/1996/000881A AP9600881A AP756A AP 756 A AP756 A AP 756A AP 9600881 A AP9600881 A AP 9600881A AP 756 A AP756 A AP 756A
Authority
AP
ARIPO
Prior art keywords
compounds
group
alkyl
growth hormone
phenyl
Prior art date
Application number
APAP/P/1996/000881A
Other languages
English (en)
Other versions
AP9600881A0 (en
Inventor
Philip A Carpino
Silva-Jardine Paul Andrew Da
Bruce Allen Lefker
John A Ragan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600881A0 publication Critical patent/AP9600881A0/xx
Application granted granted Critical
Publication of AP756A publication Critical patent/AP756A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cooling Or The Like Of Electrical Apparatus (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
APAP/P/1996/000881A 1995-12-28 1996-11-14 Dipeptide compounds which are growth hormone secretagoques. AP756A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US946995P 1995-12-28 1995-12-28

Publications (2)

Publication Number Publication Date
AP9600881A0 AP9600881A0 (en) 1997-01-31
AP756A true AP756A (en) 1999-08-06

Family

ID=21737850

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1996/000881A AP756A (en) 1995-12-28 1996-11-14 Dipeptide compounds which are growth hormone secretagoques.
APAP/P/1999/001555A AP860A (en) 1995-12-28 1999-05-27 Dipeptide compounds which are growth hormone secretegoques.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001555A AP860A (en) 1995-12-28 1999-05-27 Dipeptide compounds which are growth hormone secretegoques.

Country Status (43)

Country Link
US (7) US6107306A (de)
EP (1) EP0869968B1 (de)
JP (2) JP3511382B2 (de)
KR (1) KR100320167B1 (de)
CN (1) CN1113895C (de)
AP (2) AP756A (de)
AR (2) AR004367A1 (de)
AT (1) ATE361314T1 (de)
AU (1) AU716934B2 (de)
BG (1) BG64055B1 (de)
BR (1) BR9612465B1 (de)
CA (1) CA2241725C (de)
CO (1) CO4480108A1 (de)
CZ (1) CZ293423B6 (de)
DE (1) DE69637063T2 (de)
DK (1) DK0869968T3 (de)
EG (1) EG24195A (de)
ES (1) ES2285715T3 (de)
GT (1) GT199600100A (de)
HN (1) HN1996000085A (de)
HR (1) HRP960618B1 (de)
HU (1) HUP9901246A3 (de)
IL (4) IL138911A (de)
IS (1) IS4758A (de)
MA (1) MA26415A1 (de)
MX (1) MX9805157A (de)
MY (1) MY135727A (de)
NO (1) NO325135B1 (de)
NZ (1) NZ322172A (de)
OA (1) OA10702A (de)
PE (1) PE30398A1 (de)
PL (1) PL186916B1 (de)
PT (1) PT869968E (de)
RS (1) RS49926B (de)
SA (1) SA97170581B1 (de)
SI (1) SI0869968T1 (de)
SK (1) SK285678B6 (de)
TN (1) TNSN96172A1 (de)
TR (1) TR199801233T2 (de)
TW (1) TW432073B (de)
UA (1) UA66754C2 (de)
WO (1) WO1997024369A1 (de)
ZA (1) ZA9610858B (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
ES2363230T3 (es) 1997-04-15 2011-07-27 Csir Métodos no terapéuticos para suprimir el apetito.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
DE69837264T2 (de) 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6893877B2 (en) * 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
WO1999036431A1 (en) 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
YU73200A (sh) * 1998-06-03 2003-02-28 Pfizer Products Inc. 2-aminopiridini koji sadrže spojene ciklične supstituente kao inhibitori nitro oksid sintaze
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
OA11569A (en) * 1998-06-16 2004-07-01 Pfizer Prod Inc Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1156808A2 (de) * 1998-09-02 2001-11-28 Merck & Co., Inc. Verbesserung der rückkehr zu unabhängigen lebensbedingungen mit einem wachstumshormon-sekretagog
WO2000015273A1 (de) 1998-09-11 2000-03-23 Gerhard Schmidmaier Biologisch aktive implantate
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
US6297380B1 (en) 1998-11-23 2001-10-02 Pfizer Inc. Process and intermediates for growth hormone secretagogues
SI1004583T1 (en) * 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
CA2362290A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
MXPA02000938A (es) * 1999-07-26 2004-03-19 Baylor College Medicine Analogo super-activo de la hormona que libera la hormona de crecimiento porcina.
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
EP1113007A1 (de) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
EP1258250B1 (de) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nervenschutzmittel
WO2001061054A2 (en) * 2000-02-18 2001-08-23 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en) * 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
EP1132388A3 (de) 2000-03-09 2004-03-03 Pfizer Products Inc. Metaboliten von Hexahydropyrazolo[4,3-c]pyridinen
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
EP1280777B1 (de) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
DOP2001000154A (es) * 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (de) * 2000-06-29 2002-04-10 Pfizer Products Inc. Verwendung von wachstumshormonsekretion-fördernden mitteln zur appetit erholung
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
EP1313473A2 (de) * 2000-08-30 2003-05-28 Pfizer Products Inc. Arzneizusammensetzungen mit verzögerter wirkstoffabgabe für wachstumshormonsekretionsförderer
EP1192943A3 (de) * 2000-09-28 2002-11-27 Pfizer Products Inc. Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
EP1330306A2 (de) * 2000-10-10 2003-07-30 BioTrove, Inc. Vorrichtung zum testen, synthese und lagerung sowie verfahren zur herstellung, verwendung und handhabung
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) * 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
AU2003218337A1 (en) * 2002-04-09 2003-10-27 Eli Lilly And Company Growth hormone secretagogues
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US8277753B2 (en) * 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
US20060094108A1 (en) * 2002-12-20 2006-05-04 Karl Yoder Thermal cycler for microfluidic array assays
WO2004074818A2 (en) 2002-12-20 2004-09-02 Biotrove, Inc. Assay apparatus and method using microfluidic arrays
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) * 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
US7129561B2 (en) * 2003-11-19 2006-10-31 International Business Machines Corporation Tri-metal and dual-metal stacked inductors
EP1735097B1 (de) 2004-03-12 2016-11-30 Life Technologies Corporation Ladung eines nanoliter-arrays
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
EP1789409A4 (de) * 2004-04-02 2010-09-08 Elixir Pharmaceuticals Inc Sulfonamide und deren verwendungen
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
RU2007107349A (ru) 2004-07-28 2008-09-10 Глэксо Груп Лимитед (GB) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
WO2006023608A2 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US20090181888A1 (en) * 2005-11-21 2009-07-16 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2007106385A2 (en) * 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
CA2662449A1 (en) * 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
EP2072519A4 (de) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diarylketiminderivat
KR20090085599A (ko) * 2006-10-02 2009-08-07 바이엘 쉐링 파마 악티엔게젤샤프트 Pet 영상화용 규소 유도체
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
EP2146753A2 (de) * 2007-03-01 2010-01-27 Bayer Schering Pharma Aktiengesellschaft 18f-fluor-benzoyl-markierte biologische wirkstoffe als diagnostische bildgebungs-mittel sowie benzotriazol-1-yloxy-benzoyl , 2,5-dioxo-pyrrolidin-1-yloxy)benzoyl und trimethylammonio-benzoyl-vorläufer davon
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2002835A1 (de) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolopyridinderivate als NADPH-Oxidasehemmer
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
JP5529014B2 (ja) * 2007-06-12 2014-06-25 中国人民解放▲軍▼▲軍▼事医学科学院毒物▲薬▼物研究所 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Msd株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
EP2166010A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2165707A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
EP2166009A1 (de) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolopyridinderivate als NADPH-Oxidasehemmer
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
EP2305679A1 (de) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazolindionderivate als NADPH-Oxidasehemmer
EP2361911A1 (de) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolopiperidinderivate als NADPH-Oxidasehemmer
EP2361912A1 (de) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolopiperidinderivate als NADPH-Oxidasehemmer
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2540721B1 (de) 2010-02-26 2016-12-14 RaQualia Pharma Inc. Ghrelin rezeptor agonist für die behandlung von cachexia
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
MX2013012259A (es) * 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
TW201400506A (zh) * 2012-05-25 2014-01-01 Raqualia Pharma Inc 用於治療胃酸缺乏症之生長激素釋放肽受體促效劑
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3524260B1 (de) 2012-09-27 2023-09-13 Elanco Animal Health Incorporated Pharmazeutische zusammensetzungen zur behandlung von appetitlosigkeit
IN2015DN04172A (de) 2012-10-24 2015-10-16 Daiichi Sankyo Companyltd
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
TWI629982B (zh) * 2013-05-28 2018-07-21 拉夸里亞創藥股份有限公司 多晶型形式
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106459147B (zh) * 2014-08-05 2021-08-06 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的丝氨酸衍生物
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP2017532350A (ja) * 2014-10-31 2017-11-02 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP0662481A1 (de) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidine und ihre Homolgen die die Ausschüttung von Wachstumshormonen stimulieren.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK139625B (da) * 1971-05-11 1979-03-19 Sandoz Ag Analogifremgangsmåde til fremstilling af cycloalkan(c)pyridazin- eller pyrido(4,3-c)pyridazinderivater eller syreadditionssalte deraf.
DE2221808C2 (de) * 1972-05-04 1985-06-20 Sandoz-Patent-GmbH, 7850 Lörrach Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
JP3670690B2 (ja) * 1993-10-04 2005-07-13 トーアエイヨー株式会社 3−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
AU8083694A (en) * 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5767118A (en) * 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ATE272069T1 (de) * 1995-01-27 2004-08-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
WO1996024587A1 (en) * 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) * 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU6772996A (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU6724496A (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (de) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidine und ihre Homolgen die die Ausschüttung von Wachstumshormonen stimulieren.
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone

Also Published As

Publication number Publication date
MA26415A1 (fr) 2004-12-20
IS4758A (is) 1998-05-26
ATE361314T1 (de) 2007-05-15
NO325135B1 (no) 2008-02-04
NO982991D0 (no) 1998-06-26
JPH11501945A (ja) 1999-02-16
US20020049196A1 (en) 2002-04-25
CO4480108A1 (es) 1997-07-09
HN1996000085A (es) 1997-06-18
NZ322172A (en) 2000-08-25
ES2285715T3 (es) 2007-11-16
HRP960618A2 (en) 1998-04-30
IL138911A0 (en) 2001-11-25
BG64055B1 (bg) 2003-11-28
GT199600100A (es) 1998-06-12
US6306875B1 (en) 2001-10-23
AP860A (en) 1999-08-06
HUP9901246A3 (en) 1999-11-29
KR19990076846A (ko) 1999-10-25
UA66754C2 (en) 2004-06-15
BR9612465A (pt) 1999-07-13
US6107306A (en) 2000-08-22
ZA9610858B (en) 1998-06-23
KR100320167B1 (ko) 2003-11-14
US6482825B2 (en) 2002-11-19
DK0869968T3 (da) 2007-09-10
CZ293423B6 (cs) 2004-04-14
IL138911A (en) 2007-07-24
EG24195A (en) 2008-10-14
PL327634A1 (en) 1998-12-21
IL124449A (en) 2004-06-01
YU70296A (en) 1999-11-22
JP2001213800A (ja) 2001-08-07
MX9805157A (es) 1998-10-31
JP3511382B2 (ja) 2004-03-29
AP9600881A0 (en) 1997-01-31
DE69637063D1 (de) 2007-06-14
HRP960618B1 (en) 2007-12-31
HUP9901246A2 (hu) 1999-08-30
RS49926B (sr) 2008-09-29
WO1997024369A1 (en) 1997-07-10
EP0869968B1 (de) 2007-05-02
CN1113895C (zh) 2003-07-09
TW432073B (en) 2001-05-01
CZ199598A3 (cs) 1999-05-12
NO982991L (no) 1998-08-26
TR199801233T2 (xx) 1998-10-21
IL138910A0 (en) 2001-11-25
EP0869968A1 (de) 1998-10-14
SI0869968T1 (sl) 2007-08-31
MY135727A (en) 2008-06-30
SK285678B6 (sk) 2007-06-07
PT869968E (pt) 2007-07-11
AR052506A2 (es) 2007-03-21
US6124264A (en) 2000-09-26
DE69637063T2 (de) 2008-02-07
OA10702A (en) 2001-05-07
IL124449A0 (en) 1998-12-06
PE30398A1 (es) 1998-07-21
SA97170581B1 (ar) 2006-03-15
SK87498A3 (en) 1999-08-06
TNSN96172A1 (fr) 2005-03-15
BG102533A (en) 1999-09-30
CN1206422A (zh) 1999-01-27
AR004367A1 (es) 1998-11-04
CA2241725A1 (en) 1997-07-10
AU716934B2 (en) 2000-03-09
US6110932A (en) 2000-08-29
AP9901555A0 (en) 1999-06-30
BR9612465B1 (pt) 2010-08-10
US6313140B1 (en) 2001-11-06
US6278000B1 (en) 2001-08-21
AU7585096A (en) 1997-07-28
IL138909A0 (en) 2001-11-25
PL186916B1 (pl) 2004-03-31
CA2241725C (en) 2002-06-18

Similar Documents

Publication Publication Date Title
AP756A (en) Dipeptide compounds which are growth hormone secretagoques.
JP5000848B2 (ja) グレリン含有医薬組成物
ES2333097T3 (es) Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
US20230120030A1 (en) Long-Acting Adrenomedullin Derivatives
US6071926A (en) Sleep quality improvement using a growth hormone secretagogue
JPH10509152A (ja) 低分子量ペプチド様成長ホルモン放出促進物質
EP3271015B1 (de) Nk-3-rezeptorantagonisten zur therapeutischen oder kosmetischen behandlung von übermässigem körperfett
EP1781311A2 (de) Wachstumshormonsekretagoge
AU711884B2 (en) Enhancement of sleep with a growth hormone secretagogue
KR101228229B1 (ko) 성장 호르몬 분비 촉진물질 및 그의 용도
JP2003335752A (ja) 成長ホルモン分泌促進薬
US20070270341A1 (en) Parathyroid hormone analogues and methods of use
AU2004281084B2 (en) Use of growth hormone releasing factor analogs in treating patients suffering from wasting
AU2003229724B2 (en) Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
EP1184035A2 (de) Verwendung von Sekretionsfördermitteln für Wachstumshormone zu Behandlung des physischen Leistungsabbaus
WO2001089570A2 (en) Combination of growth hormone secretagogues and antidepressants
AU6133299A (en) Enhancement of return to independent living status with a growth hormone secretagogue
EP1716887B1 (de) Behandlung von Einschlusskörper-Myositis
CA2335112A1 (en) Therapeutic combinations for musculoskeletal frailty
US20020160961A1 (en) Compositions for the treatment of the catabolic state of prolonged critical illness
EA044055B1 (ru) Применение антагониста рецептора нейрокинина-3 (nk-3) для повышения уровней циркулирующего лептина у пациентов
Kinter et al. Toxicity of desmopressin and related peptides
RU98112108A (ru) Стимуляторы секреции гормона роста